ESD for Colorectal LSL Using a Selective Strategy - a Prospective Cohort Study (COVERT)
Primary Purpose
Colorectal Neoplasm, Endoscopic Mucosal Resection
Status
Recruiting
Phase
Not Applicable
Locations
Australia
Study Type
Interventional
Intervention
Endoscopic Submucosal Dissection
Endoscopic Mucosal Resection
Sponsored by
About this trial
This is an interventional treatment trial for Colorectal Neoplasm
Eligibility Criteria
Inclusion Criteria:
- All patients referred for colorectal resection of large laterally spreading lesions in colon.
- Can give informed consent to trial participation
Exclusion Criteria:
- Previous resection or attempted resection of target adenoma lesion
- Endoscopic appearance of invasive malignancy
- Age less than 18 years
- Pregnancy
- Active Inflammatory colonic conditions (e.g. inflammatory bowel disease)
- Use of anticoagulant or antiplatelet agents other than aspirin outside of internationally recognised guidelines
- American Society of Anesthesiology (ASA) Grade IV-V
Sites / Locations
- Westmead Endoscopy UnitRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
ESD
EMR
Arm Description
Lesion with overt stigmata of SMIC or those with high risk (=> 10%) for covert SMIC.
Lesion with no overt or a low risk for (<10%) for covert SMIC
Outcomes
Primary Outcome Measures
Rate of surgical referral
Incidence of surgical referral due to non-curative endoscopic resection.
Secondary Outcome Measures
R0 resection rate
Rate of en-bloc resection with clear resection margins.
En Bloc resection rate
Rate of en-bloc resection
Technical success rate
Rate of procedures completed as per protocol
Duration of procedure
Procedure duration in minutes.
Adenoma recurrence rate
Rate of recurrent adenoma at resection site on follow-up.
Full Information
NCT ID
NCT04008407
First Posted
July 2, 2019
Last Updated
June 28, 2023
Sponsor
Western Sydney Local Health District
1. Study Identification
Unique Protocol Identification Number
NCT04008407
Brief Title
ESD for Colorectal LSL Using a Selective Strategy - a Prospective Cohort Study
Acronym
COVERT
Official Title
Endoscopic Submucosal Dissection for Sessile Polyps and Laterally Spreading Lesions of the Colorectum Using a Selective Strategy - a Prospective Cohort Study
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 14, 2017 (Actual)
Primary Completion Date
August 2027 (Anticipated)
Study Completion Date
February 2028 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Western Sydney Local Health District
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Colonic Laterally spreading lesions (LSL) => 20mm are at high risk to progress to cancer. Overt stigmata of submucosal invasive cancer (SMIC) has been well characterized and includes ulceration and surface pit pattern changes as per the Kudo classification of type V.
In a recent report, risk factors for LSL with SMIC and no overt stigmata (i.e. covert SMIC) were described. Resection of these lesions 'en-bloc' can allow for better histological staging and potentially reduce the need for surgical resection.
Detailed Description
With over 14,000 patients diagnosed annually, colorectal carcinoma (CRC) is the second most frequently invasive malignancy in Australia. By not only diagnosing CRC at an early stage, but also removing precursor adenomas, colonoscopy with polypectomy reduces the risk of developing and dying from CRC.
Laterally spreading lesions >= 20mm (LSL) are more likely to progress to cancer. The prevalence of LSL ranges from 1-5% in screening population. The risk of malignant progression of colorectal adenomas found during colonoscopy increases with lesion size, i.e. the cancer preventive effect is likely to be maximal in large lesions. Patients with LSL have a higher risk of malignancy and a higher recurrence rate of adenoma after lesion removal compared with diminutive polyps.
Endoscopic imaging can now accurately predict LSL with submucosal invasive cancer (SMIC) through assessment of LSLs morphology (Paris classification, granularity) and surface pit-pattern (Kudo classification). Such cases can be considered to have LSL with overt risk of SMIC.
Recent publication has highlighted that some LSLs might hrbor SMIC without overt morphological features (i.e. high risk for covert SMIC). These LSL with high risk of covert SMIC stratified LSLs based on lesion location and lesion morphology.
Generally LSLs can be safely and effectively removed by wide field endoscopic mucosal resection (WF-EMR) in over 90% of cases in competent hands.
One of the draw backs with WF-EMR is it requires piecemeal resection and thus is limited in providing assessment of complete excision and depth of submucosal invasion in cases where SMIC is present.
Thus, endoscopic en-bloc resection is preferable from an oncologic standpoint to obtain a single specimen for proper histopathologic assessment. Endoscopic submucosal dissection (ESD) is a technique that is now becoming the preferred method for achieving a complete endoscopic and histologic resection, referred to as R0. Evidence from retrospective cohort and meta-analyses suggests ESD provides a more consistent oncologic resection with a reduced rate of recurrence. However, the major limitations with the technique relate to increased procedure time and the skill-set required for performing the procedure.
One of the other major limitations of ESD is significant cost associated with the procedure, which includes procedure time and additional equipment in addition to the treatment of any subsequent complications. As such the implementation of ESD as the standard of care for all colorectal lesions has not been undertaken in Western countries, however it may have an important role for selective cases especially where there is concern for sub-mucosal invasive cancer (SMIC).
The investigators propose a selective ESD strategy to be performed for patients focusing on overt evidence of SMIC and those at high risk of covert SMIC (defined as risk >10%). The investigators will follow a prospective cohort study assessing the use of selective ESD strategy in the colorectum in the Western population.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Neoplasm, Endoscopic Mucosal Resection
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Selective treatment algorithm of ESD or EMR according to risk stratification.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
391 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
ESD
Arm Type
Active Comparator
Arm Description
Lesion with overt stigmata of SMIC or those with high risk (=> 10%) for covert SMIC.
Arm Title
EMR
Arm Type
Active Comparator
Arm Description
Lesion with no overt or a low risk for (<10%) for covert SMIC
Intervention Type
Procedure
Intervention Name(s)
Endoscopic Submucosal Dissection
Other Intervention Name(s)
ESD
Intervention Description
Endoscopic Submucosal Dissection (ESD) results in en-bloc resection of LSL, regardless of lesion size. This allows for accurate histopathological assessment of SMIC, R0/R1 resection and depth of invasion. ESD is considered a potentially curative for superficial cancers (T1a).
Intervention Type
Procedure
Intervention Name(s)
Endoscopic Mucosal Resection
Other Intervention Name(s)
EMR
Intervention Description
EMR is the current standard for treating colonic LSL and has been validated to be safe and efficacious. LSLs => 20mm are frequently resected piecemeal. Recent research show that resection margin soft coagulation reduces recurrence rates to those similar to en-bloc resections.
Primary Outcome Measure Information:
Title
Rate of surgical referral
Description
Incidence of surgical referral due to non-curative endoscopic resection.
Time Frame
3 months post procedure
Secondary Outcome Measure Information:
Title
R0 resection rate
Description
Rate of en-bloc resection with clear resection margins.
Time Frame
3 months post procedure
Title
En Bloc resection rate
Description
Rate of en-bloc resection
Time Frame
3 months post procedure
Title
Technical success rate
Description
Rate of procedures completed as per protocol
Time Frame
3 months post procedure
Title
Duration of procedure
Description
Procedure duration in minutes.
Time Frame
procedure
Title
Adenoma recurrence rate
Description
Rate of recurrent adenoma at resection site on follow-up.
Time Frame
3 years post procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All patients referred for colorectal resection of large laterally spreading lesions in colon.
Can give informed consent to trial participation
Exclusion Criteria:
Previous resection or attempted resection of target adenoma lesion
Endoscopic appearance of invasive malignancy
Age less than 18 years
Pregnancy
Active Inflammatory colonic conditions (e.g. inflammatory bowel disease)
Use of anticoagulant or antiplatelet agents other than aspirin outside of internationally recognised guidelines
American Society of Anesthesiology (ASA) Grade IV-V
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michael J Bourke, Prof.
Phone
+61288905555
Email
endoscopyresearch.westmead@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Iddo Bar-Yishay, MD
Phone
+61288905555
Email
iddo.baryishay@health.nsw.gov.au
Facility Information:
Facility Name
Westmead Endoscopy Unit
City
Westmead
State/Province
New South Wales
ZIP/Postal Code
2145
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Iddo Bar-Yishay, MD
Phone
88905555
Email
iddo.baryishay@health.nsw.gov.au
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
8247072
Citation
Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993 Dec 30;329(27):1977-81. doi: 10.1056/NEJM199312303292701.
Results Reference
result
PubMed Identifier
22356322
Citation
Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012 Feb 23;366(8):687-96. doi: 10.1056/NEJMoa1100370.
Results Reference
result
PubMed Identifier
10840302
Citation
Iishi H, Tatsuta M, Iseki K, Narahara H, Uedo N, Sakai N, Ishikawa H, Otani T, Ishiguro S. Endoscopic piecemeal resection with submucosal saline injection of large sessile colorectal polyps. Gastrointest Endosc. 2000 Jun;51(6):697-700. doi: 10.1067/mge.2000.104652.
Results Reference
result
PubMed Identifier
22945585
Citation
Risio M. The natural history of colorectal adenomas and early cancer. Pathologe. 2012 Nov;33 Suppl 2:206-10. doi: 10.1007/s00292-012-1640-6.
Results Reference
result
PubMed Identifier
21392504
Citation
Moss A, Bourke MJ, Williams SJ, Hourigan LF, Brown G, Tam W, Singh R, Zanati S, Chen RY, Byth K. Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia. Gastroenterology. 2011 Jun;140(7):1909-18. doi: 10.1053/j.gastro.2011.02.062. Epub 2011 Mar 8.
Results Reference
result
PubMed Identifier
25763831
Citation
Nanda KS, Tutticci N, Burgess NG, Sonson R, Williams SJ, Bourke MJ. Endoscopic mucosal resection of laterally spreading lesions involving the ileocecal valve: technique, risk factors for failure, and outcomes. Endoscopy. 2015 Aug;47(8):710-8. doi: 10.1055/s-0034-1391732. Epub 2015 Mar 12.
Results Reference
result
PubMed Identifier
25848926
Citation
Oka S, Tanaka S, Saito Y, Iishi H, Kudo SE, Ikematsu H, Igarashi M, Saitoh Y, Inoue Y, Kobayashi K, Hisabe T, Tsuruta O, Sano Y, Yamano H, Shimizu S, Yahagi N, Watanabe T, Nakamura H, Fujii T, Ishikawa H, Sugihara K; Colorectal Endoscopic Resection Standardization Implementation Working Group of the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan. Local recurrence after endoscopic resection for large colorectal neoplasia: a multicenter prospective study in Japan. Am J Gastroenterol. 2015 May;110(5):697-707. doi: 10.1038/ajg.2015.96. Epub 2015 Apr 7.
Results Reference
result
PubMed Identifier
22278105
Citation
Lee EJ, Lee JB, Lee SH, Youk EG. Endoscopic treatment of large colorectal tumors: comparison of endoscopic mucosal resection, endoscopic mucosal resection-precutting, and endoscopic submucosal dissection. Surg Endosc. 2012 Aug;26(8):2220-30. doi: 10.1007/s00464-012-2164-0. Epub 2012 Jan 26.
Results Reference
result
PubMed Identifier
22098630
Citation
Terasaki M, Tanaka S, Oka S, Nakadoi K, Takata S, Kanao H, Yoshida S, Chayama K. Clinical outcomes of endoscopic submucosal dissection and endoscopic mucosal resection for laterally spreading tumors larger than 20 mm. J Gastroenterol Hepatol. 2012 Apr;27(4):734-40. doi: 10.1111/j.1440-1746.2011.06977.x.
Results Reference
result
PubMed Identifier
28583826
Citation
Burgess NG, Hourigan LF, Zanati SA, Brown GJ, Singh R, Williams SJ, Raftopoulos SC, Ormonde D, Moss A, Byth K, Mahajan H, McLeod D, Bourke MJ. Risk Stratification for Covert Invasive Cancer Among Patients Referred for Colonic Endoscopic Mucosal Resection: A Large Multicenter Cohort. Gastroenterology. 2017 Sep;153(3):732-742.e1. doi: 10.1053/j.gastro.2017.05.047. Epub 2017 Jun 2.
Results Reference
result
Learn more about this trial
ESD for Colorectal LSL Using a Selective Strategy - a Prospective Cohort Study
We'll reach out to this number within 24 hrs